What’s in Juniper Pharmaceuticals, Inc. (JNP) After Touching 52-Week High?

March 17, 2018 - By Kurt Siggers

The stock of Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) hit a new 52-week high and has $12.51 target or 3.00 % above today’s $12.15 share price. The 9 months bullish chart indicates low risk for the $133.35 million company. The 1-year high was reported on Mar, 17 by Barchart.com. If the $12.51 price target is reached, the company will be worth $4.00M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock decreased 2.80% or $0.35 during the last trading session, reaching $12.15. About 134,983 shares traded or 75.43% up from the average. Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) has declined 42.39% since March 17, 2017 and is downtrending. It has underperformed by 59.09% the S&P500.

Analysts await Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) to report earnings on May, 3. They expect $0.02 earnings per share, up 115.38 % or $0.15 from last year’s $-0.13 per share. JNP’s profit will be $219,505 for 151.88 P/E if the $0.02 EPS becomes a reality. After $0.11 actual earnings per share reported by Juniper Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -81.82 % negative EPS growth.

Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) Ratings Coverage

Among 5 analysts covering Juniper Pharmaceuticals Inc (NASDAQ:JNP), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Juniper Pharmaceuticals Inc had 7 analyst reports since August 26, 2015 according to SRatingsIntel. The firm has “Outperform” rating given on Tuesday, January 26 by Northland Capital. The stock of Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) has “Market Perform” rating given on Monday, January 9 by Bernstein. Roth Capital initiated the shares of JNP in report on Tuesday, January 2 with “Buy” rating. Northland Capital downgraded Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) on Thursday, August 18 to “Market Perform” rating. TheStreet upgraded the shares of JNP in report on Wednesday, August 26 to “Buy” rating. The firm earned “Neutral” rating on Friday, August 19 by H.C. Wainwright.

Juniper Pharmaceuticals, Inc., a womenÂ’s health therapeutic company, focuses on developing therapeutics that address unmet medical needs in women's health. The company has market cap of $133.35 million. The firm develops its products using its drug delivery technologies, including bioadhesive delivery system, a polymer designed to adhere to epithelial surfaces or mucosa for sustained and controlled delivery of active drug product; and a novel intra-vaginal ring technology. It currently has negative earnings. It markets CRINONE, a progesterone bioadhesive vaginal gel for progesterone supplementation or replacement as part of an assisted reproductive technology treatment for infertile women with progesterone deficiency.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.